Skip to main
MIST
MIST logo

MIST Stock Forecast & Price Target

MIST Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Milestone Pharmaceuticals Inc. has demonstrated statistically significant improvements in patient-reported outcomes related to the treatment of paroxysmal supraventricular tachycardia (PSVT), establishing a strong basis for confidence in the commercial viability of its lead product, etripamil. The company is well-positioned for a successful launch, supported by FDA agreement on a streamlined Phase 3 program for atrial fibrillation with rapid ventricular rate (AFib-RVR) and upcoming major medical conferences that may enhance visibility and market engagement. Furthermore, ongoing trials, like NODE-303, continue to reinforce the safety and efficacy of etripamil, suggesting robust potential for value creation as clinical milestones are achieved.

Bears say

Milestone Pharmaceuticals faces a challenging financial outlook due to the underappreciation of its lead product, etripamil, despite its potential benefit in addressing the urgent unmet medical need for patients experiencing paroxysmal supraventricular tachycardia (PSVT). The company's ongoing trials indicate that although etripamil can significantly reduce heart rates rapidly, reliance on medication-based management remains high, with a marked portion of patients not opting for more invasive treatments like catheter ablation. Additionally, market hesitance may be compounded by the overall competitive landscape for cardiovascular drugs and the slow adoption of newer therapies, potentially impeding the company’s revenue generation and stock performance.

MIST has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Milestone Pharmaceuticals Inc (MIST) Forecast

Analysts have given MIST a Buy based on their latest research and market trends.

According to 6 analysts, MIST has a Buy consensus rating as of Aug 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Milestone Pharmaceuticals Inc (MIST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.